ROLE OF OBESITY IN THE DEVELOPMENT OF METABOLIC DISORDERS, IN THE PROGRESSION OF LIVER FIBROSIS, AND IN THE OUTCOMES OF ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To reveal the impact of obesity on metabolic parameters, the progression of fibrosis in patients with chronic hepatitis C (CHC) and the outcomes of antiviral therapy. Subjects and methods. The investigation enrolled 205 patients aged 18 to 69 years with CHC. Laboratory indices were comparatively analyzed in patients with CHC (n = 53) and in those without this condition (n = 152). A control group consisted of obese patients (n = 44). Whether insulin resistance (IR), metabolic syndrome, and abdominal obesity were related to body mass index was analyzed. An OMRON BF508 body composition monitor (Japan) was used to estimate the percentage of adipose tissue and visceral fat tissue in the body. Results. IR syndrome, steatosis, and the higher values of fibrosis and histological activity were significantly more frequently observed in 53 (25.9%) obese patients with CHC. Metabolic syndrome, liver cirrhosis, and a low response to antiviral therapy were more common when obesity was concurrent with IR. With higher visceral fat tissue levels, the percentage of patients with IR and other components of MS increased and the response rate to antiviral therapy was lower. Conclusion. Obesity in patients with CHC leads to marked impairments in metabolic parameters and a low response to antiviral therapy and is significantly more frequently associated with liver cirrhosis.

Full Text

Restricted Access

About the authors

L. I TKACHENKO

Stavropol State Medical University

Email: larisa308@mail.ru

V. V MALEEV

Central Research Institute of Epidemiology

Email: maleyev@pcr.ru

T. N TSVETKOVSKAYA

Center for Family Health and Reproduction, Stavropol Territorial Clinical Consulting and Diagnostic Center

Email: tnc1018@yandex.ru

References

  1. Obesity and overweight. Fact sheet № 311, 2013. http://www.who.int
  2. Аметов А.С. Избранные лекции по эндокринологии. М.: МИА, 2012: 14-39.
  3. Branca F., Nikogosian H., Lobstein T. (ред.). Проблема ожирения в Европейском регионе ВОЗ и стратегии ее решения. Пер. с англ. ВОЗ, 2009. 392 с.
  4. Драпкина О.М., Смирин В.И., Ивашкин В.Т. Патогенез, лечение и эпидемиология НАЖБП - что нового? Эпидемиология НАЖБП в России. РМЖ. Болезни органов пищеварения 2011; 19(28): 1717-1721.
  5. Ertle J., Dechêne A., Sowa J.P., Penndorf V., Herzer K., Kaiser G. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int. J. Cancer 2011; 128(10): 2436-2443.
  6. Hamaguchi M., Kojima T., Takeda N. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143 (2): 722-728.
  7. Mendez-Sanchez N., Arresse M., Zamora-Valdés D., Uribe M. Current concept in pathogenesis of nonalcoholic fatty liver disease. Liver Intern. 2007; 27 (4): 423-433.
  8. Cobbold J.F., Cox I.J., Brown A.S., Williams H.R., Goldin R.D., Thomas H.C., Thursz M.R., Taylor-Robinson S.D. Lipid profiling of pre-treatment liver biopsy tissue predicts sustained virological response in patients with chronic hepatitis C. Hepatol. Res. 2012; 42(7): 714-720.
  9. Mari A., Ahren B., Pacini G. Assessments of insulin secretion in relation to insulin resistance. Curr. Opin Clin. Metab. Care. Sep. 2005; 8(5): 529-533.
  10. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier PJ., Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005; 16: 713-716.
  11. Gallagher D., Heymsfield S.B., Heo M., Jebb S.A., Murgatroyd P.R., Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am. J. Clin. Nutr. 2000; 72: 694-701.
  12. Бутрова С.А., Дзгоева Ф.Х. Висцеральное ожирение - ключевое звено метаболического синдрома. Ожирение и метаболизм 2004; 1: 10-16.
  13. Fierbinţeanu-Braticevici C., Mohora L.M., Tribus А., Petritor A., Sanda M., Cretoiu D., Usvat R., Ioniţă L. Hepatocyte steatosis in patients infected with genotype 1 hepatitis C virus. Rom. J. Morphol. Embryol. 2010; 51(2): 235-242.
  14. Hourigan L.F., Macdonald G.A., Purdie D., Whitehall V.H., Shorthouse C., Clouston A., Powell E.E. Fibrosis in Chronic Hepatitis C Correlates Significantly With Body Mass Index and Steatosis. Hepatology 1999; 29(4): 1215-1219.
  15. Mason A.L., Lau J.Y.N., Hoang N., Qian K., Alexander G.J., Xu L., Guo L., Jacob S., Regenstein F.G., Zimmerman R., Everhart J.E., Wasserfall C., Maclaren N.K., Perrillo R.P. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-333.
  16. Madny A.G., Adam A.A. Seroprevalence of Hepatitis C Virus among type 2 diabetes mellitus patients in blue nile state, Sudan. American Journal of Research Communication 2014; 2(12): 141-147.
  17. McCullough A.J. Obesity and its nurturing effect on hepatitis C. Hepatology 2003; 38: 557-559.
  18. Charlton M.R., Pockros P.J., Harrison S.A. Impact of Obesity on treatment of Chronic Hepatitis C. Hepatology 2006; 43: 1177-1186.
  19. Mauger J.F., Livesque J., Paradis M.E., Bergeron N., Tchernof A., Couture P., Lamarche B. Intravascular kinetics of C-reactive protein and their relationships with features of the metabolic syndrome. Clin. Endocrinol. Metab. 2008; 93(8): 3158-3164.
  20. Shoelson S.E., Herrero L., Afia Naaz. Obesity, Inflammation, and Insulin Resistance. Gastroenterology 2007; 132: 2169-2180.
  21. Pfützner A., Schöndorf T., Hanefeld M., Forst T. High-Sensitivity C-Reactive Protein Predicts Cardiovascular Risk in Diabetic and Nondiabetic Patients: Effects of Insulin-Sensitizing Treatment with Pioglitazone. J. Diabetes Sci. Technol. 2010; 4(3): 706-716.
  22. Roth C.L., Elfers C., Kratz M., Hoofnagle A.N. Vitamin d deficiency in obese children and its relationship to insulin resistance and adipokines. J. Obes. 2011; 20 (11): 495-501.
  23. George P.S., Pearson E.R., Witham M.D. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. Diabet Med. 2012; 29: 142-150.
  24. Hyppönen E., Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care 2006; 29: 2244-2246.
  25. Vimaleswaran K.S., Berry D.J., Chen Lu, Tikkanen E., Pilz S., Hirak L.T., Cooper J.D., Dastan Z., Li R., Houston D.K., Wood A.R., Michaëlsson K., Vandenput L., Zgaga L., Yerges-Armstrong L.M., McCarthy M.I., Dupuis J., Kaakinen M., Kleber M.E., Jameson K., Arden N., Raitakari O., Viikar J., Lohman K.K., Ferrucci L., Melhus H., Ingelsson E., Byberg L., Lind L., Lorentzon M., Salomaa V., Campbell H., Dunlop M., Mitchell B.D., Herzig K.-H., Pouta A., Hartikainen A.-L., the Genetic Investigation of Anthropometric Traits (GIANT) consortium, Streeten E.A., Theodoratou E., Jula A., Wareham N.J., Ohlsson C., Frayling T.M., Kritchevsky S.B., Spector T.D., Richards J.B., Lehtimäk T., Ouwehand W.H., Kraf P., Cooper C., März W., Power C., Loos R. J.F., Wang T.J., Järvelin M.-R., Whittaker J.C., Hingorani A.D., Hyppönen E. Causal relationship between obesity and vitamin D status: bidirectional Mendelian randomization analysis of multiple cohorts. PLoS Med. 2013; 10: e1001383.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies